Established nuclear medicine techniques for tumour diagnosis (tumour SPECT): Can they still compete with 18F-FDG-PET?;Konventionelle nuklear-medizinische tumordiagnostik (Tumor-SPECT): Was ist angesichts von 18F-FDG-PET noch aktuell?

NuklearMedizin

Volumn 44, Issue 1, 2005, Pages

  Schmidt, Matthias ^a   Eschner, W ^a   Dietlein, M ^a   Theissen, P ^a   Schicha, H ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

18F FDG PET; Carcinoid; GEP tumours; Merkel cell tumours; Neuroblastoma; Paraganglioma; Phaeochromozytoma; Thyroid carcinoma; Tumour SPECT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM CITRATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; THALLIUM CHLORIDE TL 201; DIAGNOSTIC AGENT;

CANCER DIAGNOSIS; CARCINOID; CELL DIFFERENTIATION; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST; GASTROINTESTINAL TUMOR; HUMAN; MERKEL CELL TUMOR; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NUCLEAR MEDICINE; PANCREAS TUMOR; PARAGANGLIOMA; PHEOCHROMOCYTOMA; REVIEW; SCINTIMAMMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TECHNIQUE; THYROID CARCINOMA; TUMOR LOCALIZATION; ARTICLE; COMPARATIVE STUDY; METHODOLOGY; NEOPLASM; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 15944400707     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Adams S, Baum R, Rink T et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998; 25: 79-83.
2. Adams S, Baum RP, Hertel A et al. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings Eur J Nucl Med 1998; 25: 1277-83.
3. 99mTc-Sestamibi scintimammography complementary to conventional mammography for detecting breast cancer in patients with palpable masses? J Nucl Med 2001; 42: 1614-21.
4. 111In-pentetreotide. J Nucl Med 2001; 42: 1134-8.
5. Bartold SP, Donohoe KJ, Fletcher JW et al. Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. J Nucl Med 1997; 38: 990-4.
6. Baulieu F, Bourlier P, Scotto B et al. The value of immunoscintigraphy in the detection of recurrent colorectal cancer. Nucl Med Comm 2001; 22: 1295-304.
7. Becker D, Charkes ND, Dworkin H et al. Procedure guideline for extended scintigraphy for differentiated thyroid cancer 1.0. J Nucl Med 1996; 37: 1269-71.
8. Bombardieri E, Aktolun C, Baum RP et al. Bone scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2003; 30: BP99-106.
9. Bombardieri E, Aktolun C, Baum RP et al. Breast scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2003; 30: BP107-14.
10. Bombardieri E, Aktolun C, Baum RP et al. FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2003; 30: BP115-24.
11. 67Ga scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2003; 30: BP125-31.
12. 123I-Metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2003; 30: BP132-9.
13. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2003; 30: BP140-7.
14. Brenot-Rossi I, Bouabdallah R, Di Stefano D et al. Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy. Eur J Nucl Med 2001; 28: 1482-8.
15. Charkes ND, Vitti RA, Brooks K. Thallium-201 SPECT increases detectability of thyroid cancer metastases. J Nucl Med 1990; 31: 147-53.
16. Chajari M, Lacroix J, Peny A-M et al. Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography. Eur J Nucl Med 2002; 29: 380-7.
17. 99mTc-Demotate 1: first data in tumour patients - results of a pilot / phase I study. Eur J Nucl Med Mol Imaging 2003; 30: 1211-9.
18. Delcambre C, Reman O, Henry-Amar M et al. Clinical Relevance of gallium-67 scintigraphy in lymphoma before and after therapy. Eur J Nucl Med 2000; 27: 176-84.
19. Diehl M, Risse JH, Brandt-Mainz K et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001; 28: 1671-6.
20. Dietlein M, Scheidhauer K, Voth E et al. Fluorine-18-fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24: 1342-8.
21. Dietlein M, Dressler J, Eschner W et al. Verfahrensanweisung für die Iod-131-Ganzkörperszintigraphie beim differenzierten Schilddrü senkarzinom (Version 2). Nuklearmedizin 2003; 42: 123-5.
22. Dietlein M, Dressler J, Farahati J et al. Verfahrensanweisung zur Radioiodtherapie (RIT) beim differenzierten Schilddrüsenkarzinom (Version 2). Nuklearmedizin 2004; 43: 115-20.
23. Donohoe KJ, Henkin RE, Royal HD et al. Procedure Guideline for Bone Scintigraphy 1.0. J Nucl Med 1996; 37: 1903-6.
24. Edwards CL, Hayes RL: Tumor scanning with 67-Ga citrate. J Nucl Med 1969; 10: 103-5.
25. Fischer M. Leitlinie für die Radionuklidtherapie bei schmerzhaften Knochenmetastasen. Nuklearmedizin 1999; 38: 270-2.
26. Förster GF, Laumann C, Nickel O et al. SPET/CT image co-registration in the abdomen with a simple and cost-effective tool. Eur J Nucl Med 2003; 30: 32-9.
27. 99mTc-MIBI in patients with multiple myeloma. Eur J Nucl Med 2001; 28: 214-20.
28. 99mTc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 2002; 43: 1012-7.
29. Franzius C, Daldrup-Link HE, Wagner-Bohn A et al. FDG-PET for the detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol 2002; 13: 157-60.
30. 18F-Fluor- Deoxyglukose (FDG-PET) in der pädiatrischen Onkologie. Der Nuklearmediziner 2002; 25: 118-21.
31. Franzius C. FDG PET: advantages for staging the mediastinum? Lung Cancer 2004; 45 (suppl 2): S69-74.
32. Freeman LM, Blaufox MD. Yttrium 90 Ibritumomab tiuxetan (Zevalin) radioimmunotherapy for B-cell Non-Hodgkin's lymphoma. Semin Nucl Med 2001; 33 (Suppl 1): 1-23.
33. Front D, Israel O, Epelbaum R et al. Ga-67 SPECT before and after treatment of lymphoma. Radiology 1990; 175: 515-9.
34. Front D, Bar-Shalom R, Mor M et al. Aggressive Non-Hodgkin lymphoma: early prediction of outcome with Ga-67 scintigraphy. Radiology 2000; 214: 253-7.
35. 18F-FDG positron emission tomography in lung and prostate cancer patients: different affinity between lytic and sclerotic bone metastases. Eur J Nucl Med Mol Imaging 2003; 30: 1714.
36. Gotthardt M, Fischer M, Naeher I et al. Use of incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med 2002; 29: 597-606.
37. Guhlke S, Famulok M, Biersack HJ. Aptamers: a novel class of radiopharmaceutical with diagnostic and therapeutic potential. Eur J Nucl Med Mol Imaging 2003; 30: 1441-3.
38. 201Tl-SPECT in evaluation of pulmonary nodules. J Nucl Med 2001; 42: 1489-96.
39. Khalkhali I, Diggles LE, Taillefer R et al. Procedure Guideline for Breast Scintigraphy. J Nucl Med 1999; 40: 1233-5.
40. Kirsch C-M. Leitlinie für die Gallium-Szintigraphie bei malignen Erkrankungen. Nuklearmedizin 1999; 38: 265-6.
41. Kirsch C-M, Hellwig D, Schaefer A. Die Form folgt der Funktion: Molekulare und morphologische Information in der konventionellen Nuklearmedizin. Der Nuklearmediziner 2003; 26: 251-8.
42. 18F- Fluordeoxyglukose (FDG). Nuklearmedizin 1999; 38: 267-9.
43. Knoop B. Leitlinie für nuklearmedizinische Bildgebung. Nuklearmedizin 1999; 38: 273-8.
44. Kopka K, Breyholz HJ, Wagner S et al. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nucl Med Biol 2004; 31: 257-67.
45. Kostakoglu L, Yeh SDJ, Portlock C et al. Validation of Gallium-67-citrate single-photon-emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med 1992; 33: 345-50.
46. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000; 27: 1564-78.
47. Kushner BH, Yeh SDJ, Kramer K et al. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003; 21: 1082-6.
48. Kwekkeboom DJ, De Jong M, Krenning EP. Somatostatin receptor scintigraphy. In: Sandler MP, Coleman RE, Patton JA et al. Diagnostic nuclear medicine. Philadelphia: Lippincott Williams Wilkins 2003; 735-46.
49. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrin Rev 1991; 12: 450-82.
50. Le Rest C, Bomanji JB, Costa DC et al. Functional imaging of malignant paragangliomas and carcinoid tumours. Eur J Nucl Med 2001; 28: 478-82.
51. 18F-FDG-PET: should the whole body scan include the legs? Nuklearmedizin 2003; 42: 167-72.
52. Lumachi F, Ferretti G, Povolato M et al. Accuracy of technetium-99m sestamibi scintimammography and x-ray mammography in premenopausal women with suspected breast cancer. Eur J Nucl Med 2001; 28: 1776-80.
53. 131I-metaiodobenzylguanidine in the treatment of neuroblastoma. Med Ped Oncol 1998; 31: 22-6.
54. 131iodine. J Nucl Med 1996; 37: 881-4.
55. 99mTc-Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 2003; 30: 247-58.
56. 123I-MIBG-Applikation. Nuklearmedizin 2002; 41: 221-3.
57. Olivier P, Colarinha P, Fettich J et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 2003; 30: BP45-50.
58. Pace L, Catalano L, Del Vecchio S et al. Predictive value of technetium-99m sestamibi in patients with multiple myeloma and potential role in the follow-up. Eur J Nucl Med 2001; 28: 304-12.
59. Palmedo H, Biersack H-J. Mamma-Szintigraphie. AWMF online Nr. 031/009.
60. Parker JA, Yester MV, Daube-Witherspoon ME et al. Procedure guideline for general imaging 1.0. J Nucl Med 1996; 37: 2087-92.
61. 99mTc-MIBI scintigraphy in musculoskeletal tumors. J Nucl Med 2001; 42: 33-7.
62. Reinartz P, Wieres F-J, Schneider W et al. Side-by-side reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT? Eur J Nucl Med Mol Imaging 2004; 31: 1456-61.
63. rd German interdisciplinary consensus conference, »Onko-PET III«, 21. July and 19 September 2000. Eur J Nucl Med 2001; 28: 1707-23.
64. Riemann B, Schober O. Cross section nuclear medicine. Nuklearmedizin 2002; 1: 1-2.
65. Sandler MP, Coleman RE, Patton JA et al. Diagnostic Nuclear Medicine. Philadelphia: Lippincott, Williams Wilkins 2003.
66. Schelbert HR, Hoh CK, Royal HD et al. Procedure guideline for tumour imaging using fluorine-18-FDG. J Nucl Med 1998; 39: 1302-5.
67. Schicha H, Schober O. Nuklearmedizin - Basiswissen und klinische Anwendung. 5. Auflage. Stuttgart: Schattauer 2003.
68. Schmidt M, Fischer E, Dietlein M et al. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. Eur J Nucl Med 2002; 29: 1571-80.
69. Schmidt M, Scheidhauer K, Luyken C et al. Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 1998; 25: 675-86.
70. Schuster DM, Alazraki N. Gallium and other agents in diseases of the lung. Semin Nucl Med 2002; 32: 193-211.
71. 99mTc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy. J Nucl Med 2002; 43: 745-51.
72. 99mTc- bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging 2003; 30: 1378-82.
73. 201Tl in diagnsis of recurrent or metastatic thyroid carcinoma. J Nucl Med 2001; 42: 414-9.
74. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998; 39: 679-88.
75. Silberstein E, Taylor A Jr. Procedure guideline for bone pain treatment 1.0. J Nucl Med 1996; 37: 881-4.
76. 99mTc-terofosmin SPECT in the detection of both primary breast cancer and axillary lymph node metastasis. Eur J Nucl Med 2001; 28: 1781-94.
77. 99mTc-Sestamibi - Indikationen und Limitationen. Nuklearmedizin 2002; 41: 148-56.
78. 67Ga SPECT. Radiology 1987; 164: 111-4.
79. Van Tinteren H, Hoekstra OS, Smit EF et al. and the PLUS study group. Effectiveness of positron enission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicenter randomised trial. Lancet 2002; 359: 1388-92.
80. 99mTc-MIBI for detecting bone marrow metastases. J Nucl Med 2002; 43: 596-602.
81. Werneke U, McCready R. Complementary alternative medicine and nuclear medicine. Eur J Nucl Med Mol Imaging 2004; 31: 599-603.
82. Wienhard K, Eriksson L, Grootoonk S et al. Performance evaluation of the positron scanner ECAT EXACT. J Comput Assist Tomograph 1992; 16: 804-13.
83. 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. J Nucl Med 2000; 41: 1657-63.